China's Type 2 Diabetes Market Will Grow to $2.5 Billion in 2014

Rising Sales from Newly Launched Western-branded Products Will Offset Generic Erosion from Older Agents, According to a New Report from Decision Resources

BURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that the Chinese type 2 diabetes market will grow from $1.4 billion in 2009 to $2.5 billion in 2014. According to the Emerging Markets report entitled Type 2 Diabetes in China, this growth is attributed to an increasing drug-treated population, expanding medical insurance coverage and the launch and adoption of new drugs in the market.

"China now has the largest type 2 diabetes patient population in the world, and is the third largest market for type 2 diabetes agents, behind the United States and Japan," said Decision Resources Analyst Jing Wu, M.S., M.B.A. "The type 2 diabetes market in China will continue to grow between 2009 and 2014 at an annual rate of 13 percent, which is faster than expected growth in the United States or Japan."

The report also finds that rising sales from newly launched Western-branded products will offset the generic erosion from older agents. The launches of three dipeptidyl peptidase-4 (DPP-IV) inhibitors—Merck's Januvia, Novartis's Galvus and Bristol-Myers Squibb/AstraZeneca's Onglyza—and two glucagon-like peptide 1 (GLP-1) analogues—Novo Nordisk's Victoza and Eli Lilly/Amylin/Alkerme's Bydureon—between 2009 and 2014 will result in more than $270 million combined sales from these two drug classes in 2014.

"Increasing economic power in China and improvements in health insurance coverage has resulted in increased access to healthcare and the ability to afford expensive Western-branded drugs," said Wu. "While metformin will continue to be the most widely prescribed agent in China because of its low cost and long-term physician familiarity, newly launched DPP-IV inhibitors and GLP-1 agonists will be used more frequently in the second or third line. The use of more Western brands will contribute to the expansion of the type 2 diabetes market in China."

The new report features extensive primary research of Chinese endocrinologists in Beijing, Shanghai, Guangzhou, Tianjin and Wuhan as well as epidemiology data.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Decision Resources, Inc.

Lisa Osgood

Christopher Comfort



[email protected]

[email protected]

SOURCE Decision Resources